Evidence map›Paper›PMID 35396316›Full record

Observational studyBMJ open2022

Histo-MRI map study protocol: a prospective cohort study mapping MRI to histology for biomarker validation and prediction of prostate cancer.

Saurabh Singh, Manju Mathew, Thomy Mertzanidou, Shipra Suman, Joey Clemente, Adam Retter, Marianthi-Vasiliki Papoutsaki, Lorna Smith, Francesco Grussu, Veeru Kasivisvanathan and 12 more

Registry-linked trialOpen access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04792138 (Learning MRI and Histology Image Mappings for Cancer Diagnosis and Prognosis), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04792138 unknown statusnot on this map

Learning MRI and Histology Image Mappings for Cancer Diagnosis and Prognosis

TypeobservationalSponsorUniversity College, LondonRan2020 to 2023Enrolled300ConditionsProstate Cancer, Prostate NeoplasmArmsVERDICT MRI, Luminal Index Imaging
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Observational
  2. Review
  3. Modern integrative prostate cancer diagnostics.Current opinion in urology · 2026
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 4 institutions in 2 countries.

Saurabh Singh *Centre for Medical Imaging, University College London, London, UK saurabh.singh@nhs.net.ORCID 0000-0002-8730-524X
Manju Mathew *Centre for Medical Imaging, University College London, London, UK.
Thomy MertzanidouCentre for Medical Imaging Computing, Department of Computer Science, University College London, London, UK.
Shipra SumanCentre for Medical Imaging, University College London, London, UK.
Joey ClementeCentre for Medical Imaging, University College London, London, UK.
Adam RetterCentre for Medical Imaging, University College London, London, UK.
Marianthi-Vasiliki PapoutsakiCentre for Medical Imaging, University College London, London, UK.
Lorna SmithCentre for Medical Imaging, University College London, London, UK.
Francesco GrussuCentre for Medical Imaging Computing, Department of Computer Science, University College London, London, UK.
Veeru KasivisvanathanDivision Of Surgery and Interventional Sciences, University College London, London, UK.ORCID 0000-0002-0832-382X
Alistair GreyDepartment of Urology, University College London Hospitals NHS Foundation Trust, London, UK.
Eoin DinneenDivision Of Surgery and Interventional Sciences, University College London, London, UK.ORCID 0000-0002-4309-3257
Greg ShawDepartment of Urology, University College London Hospitals NHS Foundation Trust, London, UK.
Martyn CarterFaculty of the Built Environment, University College London, London, UK.
Dominic PatelDepartment of Pathology, University College London Cancer Institute, London, UK.
Caroline M MooreDivision Of Surgery and Interventional Sciences, University College London, London, UK.ORCID 0000-0003-0202-7912
David AtkinsonCentre for Medical Imaging, University College London, London, UK.
Eleftheria PanagiotakiCentre for Medical Imaging Computing, Department of Computer Science, University College London, London, UK.
Aiman HaiderDepartment of Pathology, University College London Hospitals NHS Foundation Trust, London, UK.
Alex FreemanDepartment of Pathology, University College London Hospitals NHS Foundation Trust, London, UK.
Daniel AlexanderCentre for Medical Imaging Computing, Department of Computer Science, University College London, London, UK.
Shonit PunwaniCentre for Medical Imaging, University College London, London, UK.
University College London · GBUniversity College London Hospitals NHS Foundation Trust · GBLondon Cancer · GBVall d'Hebron Hospital Universitari · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMultiparametric MRI (mpMRI) is now widely used to risk stratify men with a suspicion of prostate cancer and identify suspicious regions for biopsy. However, the technique has modest specificity and a high false-positive rate, especially in men with mpMRI scored as indeterminate (3/5) or likely (4/5) to have clinically significant cancer (csPCa) (Gleason ≥3+4). Advanced MRI techniques have emerged which seek to improve this characterisation and could predict biopsy results non-invasively. Before these techniques are translated clinically, robust histological and clinical validation is required. METHODS AND ANALYSIS: This study aims to clinically validate two advanced MRI techniques in a prospectively recruited cohort of men suspected of prostate cancer. Histological analysis of men undergoing biopsy or prostatectomy will be used for biological validation of biomarkers derived from Vascular and Extracellular Restricted Diffusion for Cytometry in Tumours and Luminal Water imaging. In particular, prostatectomy specimens will be processed using three-dimension printed patient-specific moulds to allow for accurate MRI and histology mapping. The index tests will be compared with the histological reference standard to derive false positive rate and true positive rate for men with mpMRI scores which are indeterminate (3/5) or likely (4/5) to have clinically significant prostate cancer (csPCa). Histopathological validation from both biopsy and prostatectomy samples will provide the best ground truth in validating promising MRI techniques which could predict biopsy results and help avoid unnecessary biopsies in men suspected of prostate cancer. ETHICS AND DISSEMINATION: Ethical approval was granted by the London-Queen Square Research Ethics Committee (19/LO/1803) on 23 January 2020. Results from the study will be presented at conferences and submitted to peer-reviewed journals for publication. Results will also be available on ClinicalTrials.gov. TRIAL REGISTRATION NUMBER: NCT04792138.

Indexed as

Multiparametric Magnetic Resonance ImagingProstatic NeoplasmsBiomarkersHumansImage-Guided BiopsyMagnetic Resonance ImagingMaleProspective StudiesBiomarkersMagnetic resonance imagingPathologyProstate disease

Identifiers

PMID35396316
PMCPMC8995953
OpenAlexW4223444149

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.